|1.||Nuthalapati, Silpa: 1 article (09/2012)|
|2.||Cosenza, Stephen: 1 article (09/2012)|
|3.||Zhou, Qingyu: 1 article (09/2012)|
|4.||Guo, Ping: 1 article (09/2012)|
|5.||Reddy, E Premkumar: 1 article (09/2012)|
|6.||Gallo, James M: 1 article (09/2012)|
|7.||Lv, Hua: 1 article (09/2012)|
|8.||Reddy, M V Ramana: 1 article (09/2012)|
|1.||Brain Neoplasms (Brain Tumor)
09/01/2012 - "ON013100 showed high brain and brain tumor penetration with Css(brain)/Css(plasma) and Css(brain tumor)/Css(plasma) ratios of 0.92 ± 0.26 and 1.35 ± 0.40, respectively; its prodrug ON013105 showed negligible brain and brain tumor penetration. "
09/01/2012 - "To evaluate a mitotic inhibitor, ON01910.Na, as a potential chemotherapeutic agent for brain tumors using a series of PK/PD studies, which led to the evaluation of its structural analog, ON013105, a prodrug of the more lipophilic product, ON013100. "
09/01/2012 - "ON013105, not ON01910.Na, was identified as a potential anticancer drug candidate for further investigation in brain tumor chemotherapy based on the properties of ON013100."
09/01/2012 - "Using an orthotopic U87 glioma mouse model, brain and brain tumor distribution under steady-state conditions were evaluated for ON01910.Na and ON013105/ON013100; anticancer potential following a multiple-dose schedule of 250 mg/kg/day IP for 7 days was evaluated for ON01910.Na. "
|1.||Drug Therapy (Chemotherapy)